RNI 249® is a patented extract from the Maca (Lepidium meyenii) hypocotyl shown to increase endogenous levels of insulin-like growth factor 1 (IGF-1). IGF-1 naturally decreases with age and corresponds to many of the symptoms associated with the aging process. RNI 249 has implications for a variety of health concerns ranging from age-associated cognitive decline and atrophy to dynamic/static wrinkles and energy. With research supported in part by a grant from the US National Institutes of Health, RNI 249 has been shown to aide in the repair and regeneration of human arthritic cartilage cells (chondrocytes) and used successfully in a clinical trial to treat osteoarthritis of the knee.
- USPTO 8,182,847 (2012)
- Food Chemistry. 2002, 79:207-213.
- BMC Comp Alt Med. 2006, 6:13
- ISRCTN 25438351 (2006)
- BMC Comp Alt Med. 2007, 7:34
- NIH 1R43AG024733-01, 2004-2005.
Zangrado® is a patented derivative from the latex of a Croton species tree. RNI original research demonstrated its mechanism of action as regulating the sensory afferent neurons that line both the internal organs as well as skin. Orally, Zangrado has been an effective in the treatment of nausea and ulcers with implications for irritable bowel syndrome, gastroesophageal reflux disease as well as other gastrointestinal complaints. Topically, Zangrado has been clinically shown effective in reducing pain and itching associated with insect bites and stings, contact dermatitis, and plays a cicatrizing role in the healing process.
- USPTO 7,208,183 (2007)
- USPTO 7,632,524 (2009)
- USPTO 7,883,727 (2011)
- Am J Physio GI Liv Physio. 2000, 279: G192–G200.
- J Inv Derm. 2001, 117(3):725-730.
- J Ethnopharm. 2002, 80:121-129.
- J Trans Med. 2008, 6:3.
Progrado® is a natural proanthocyanidin-rich byproduct from a patented extraction process of the croton species. While its proanthocyanidin component is indicated for cardiovascular use, it has been shown to inhibit matrix metalloproteinases and cartilage degradation.
- Journal of Inflammation, 2007. 4:16.
Vincaria® is a patented, alkaloid-deplete extract from an Uncaria species liana shown in human clinical studies to reduce pain and inflammation associated with osteoarthritis. It’s mechanism of action is regulation of TNF-alpha, a cytokine responsible in over 35 inflammatory pathways, via regulation of transcription factor NFκB. In addition, It also protects the gastrointestinal tract from NSAID (e.g. aspirin) induced injury, such as ulcers. The development of this product was supported in part by a grant from the national institutes of health.
- USPTO 6,797,286 (2004)
- Inflammation Res. 2001, 50:442-448.
- JANA. 2002, 5(2):34-40.
- J Inflammation. 2005; 2:11.
- BMC Comp Alt Med. 2007, 7:34
- JANA. 2004, 7(2):32-39
- Aliment Pharm Therapeutics, 1998, 12:1279-1289.
- Free Rad Bio Med, 2000, 29:71-78,
- BMC Comp Alt Med. 2001, 1:11.
- BMC Comp Alt Med. 2007, 7:34
- NIH 1R43AG024733-01, 2004-2005.